EconStor >
Academy of Entrepreneurial Finance (AEF), Montrose, CA >
The Journal of Entrepreneurial Finance (JEF) >

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10419/55927
  

Full metadata record

DC FieldValueLanguage
dc.contributor.authorSturm, Andreasen_US
dc.contributor.authorDowling, Michael J.en_US
dc.contributor.authorRöder, Klausen_US
dc.date.accessioned2012-03-15T14:03:40Z-
dc.date.available2012-03-15T14:03:40Z-
dc.date.issued2007en_US
dc.identifier.citationJournal of Entrepreneurial Finance, JEF 1551-9570 12 2007 2 23-53en_US
dc.identifier.urihttp://hdl.handle.net/10419/55927-
dc.description.abstractWe investigated the stock price behavior of public pharmaceutical and biotechnology companies upon approval of a drug by the Food and Drug Administration (FDA). Using event study methodology, we examine the reaction caused by the approval, separating it from the asset price movements caused by other factors such as market and industry effects. The results are then used to validate the model developed in this article as an alternative to the explanations given by Sharma and Lacey (2004). The results of this study support the Efficient Market Hypothesis, i.e. that the market reacts to the new information quickly and clearly.en_US
dc.language.isoengen_US
dc.publisherMontrose, California Academy of Entrepreneurial Finance - AEFen_US
dc.subject.ddc330en_US
dc.titleFDA drug approvals: Time Is money!en_US
dc.typeArticleen_US
dc.identifier.ppn663299608en_US
dc.rightshttp://www.econstor.eu/dspace/Nutzungsbedingungenen_US
Appears in Collections:The Journal of Entrepreneurial Finance (JEF)

Files in This Item:
File Description SizeFormat
663299608.pdf378.03 kBAdobe PDF
No. of Downloads: Counter Stats
Show simple item record
Download bibliographical data as: BibTeX

Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.